HealthEquity Analysts Boost Their Forecasts After Upbeat Earnings

HealthEquity (HQY) reported strong Q1 results, exceeding analyst expectations with EPS of $0.97 and revenue of $330.8 million. The company raised its FY26 adjusted EPS guidance to $3.61-$3.78, while reiterating its revenue outlook of $1.28B-$1.3B. Following the earnings release, multiple analysts raised their price targets on HQY, with the stock price subsequently increasing by 9.8% to $113.94.

Analysis

HealthEquity, Inc. (HQY) reported a strong start to its fiscal 2026, with first-quarter financial results significantly exceeding analyst expectations. The company announced quarterly earnings of 97 cents per share, surpassing the consensus estimate of 88 cents, and quarterly revenue of $330.8 million, which beat the Street estimate of $321.17 million. CEO Scott Cutler highlighted these figures as representing record quarterly revenue and record Adjusted EBITDA. In a display of confidence, HealthEquity raised its fiscal 2026 adjusted EPS guidance from a range of $3.57-$3.74 to a new range of $3.61-$3.78, positioning the midpoint above the $3.63 analyst estimate. However, the company reiterated its full-year 2026 revenue outlook of $1.28 billion to $1.3 billion, aligning with the $1.3 billion consensus estimate. The positive earnings report and outlook prompted a significant market reaction, with HealthEquity shares gaining 9.8% to $113.94. Following the announcement, several investment banks revised their price targets upwards: JMP Securities increased its target to $117 (maintaining Market Outperform), BofA Securities to $125 (maintaining Buy), and RBC Capital to $117 (maintaining Outperform). Goldman Sachs also raised its price target to $104 but maintained a Neutral rating, with this new target now trailing the current market price.

Key Decisions for Investors

• Investors should consider HealthEquity's robust Q1 earnings, record financial metrics, and increased EPS guidance as strong positive signals for the company's operational performance and profitability outlook.
• The significant 9.8% share price appreciation to $113.94 and predominantly bullish analyst price target revisions suggest positive market sentiment, though the reiterated revenue guidance and Goldman Sachs' Neutral rating with a price target below the current market price warrant careful consideration regarding valuation.
• Evaluate the sustainability of the current stock price level against the backdrop of raised EPS guidance but unchanged revenue outlook, and monitor future quarters for continued execution and potential upward revisions to revenue forecasts.